{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lobo J"],"funding":["Fundação para a Ciência e a Tecnologia"],"pagination":["54-64"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12699239"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["268(1)"],"pubmed_abstract":["Approximately 10% of testicular Leydig cell tumors (LCTs) are clinically malignant and unresponsive to systemic treatment. Predicting their clinical behavior can be problematic because there are no biomarkers that can consistently discriminate between benign and malignant LCTs. We assessed microRNA expression profiles of LCTs to identify differentially expressed microRNAs that could potentially distinguish benign from malignant neoplasms. The study consisted of two phases. In the first (discovery) phase, we interrogated 768 microRNAs in a series of 11 LCTs (six malignant and five benign) using Taqman Low-Density Array (TLDA) microRNA profiling. In the second phase, we validated the top differentially expressed microRNA targets with real-time quantitative PCR on a series of 35 LCTs (17 mali"],"journal":["The Journal of pathology"],"pubmed_title":["MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR-196b-5p as a potentially useful biomarker."],"pmcid":["PMC12699239"],"funding_grant_id":["2022.09566.BD"],"pubmed_authors":["Lobo J","Henrique R","Anderson WJ","Colecchia M","Tavares NT","Fernandes-Pontes F","Oliveira-Lopes B","MacLean F","Ulbright TM","Michalova K","Acosta AM","Sangoi AR","Kao CS","Contreras F","Marques AT","Idrees MT","Osunkoya AO","Fonseca D","Ricci C","Cornejo KM","Gonzalez IMF","Jeronimo C","Constancio V"],"additional_accession":[]},"is_claimable":false,"name":"MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR-196b-5p as a potentially useful biomarker.","description":"Approximately 10% of testicular Leydig cell tumors (LCTs) are clinically malignant and unresponsive to systemic treatment. Predicting their clinical behavior can be problematic because there are no biomarkers that can consistently discriminate between benign and malignant LCTs. We assessed microRNA expression profiles of LCTs to identify differentially expressed microRNAs that could potentially distinguish benign from malignant neoplasms. The study consisted of two phases. In the first (discovery) phase, we interrogated 768 microRNAs in a series of 11 LCTs (six malignant and five benign) using Taqman Low-Density Array (TLDA) microRNA profiling. In the second phase, we validated the top differentially expressed microRNA targets with real-time quantitative PCR on a series of 35 LCTs (17 mali","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T02:11:19.169Z","creation":"2026-05-24T03:12:26.477Z"},"accession":"S-EPMC12699239","cross_references":{"pubmed":["41152570"],"doi":["10.1002/path.6487"]}}